ECSP045185A - Formulación oral de fludara purísimo con liberación rápida del ingrediente activo - Google Patents

Formulación oral de fludara purísimo con liberación rápida del ingrediente activo

Info

Publication number
ECSP045185A
ECSP045185A EC2004005185A ECSP045185A ECSP045185A EC SP045185 A ECSP045185 A EC SP045185A EC 2004005185 A EC2004005185 A EC 2004005185A EC SP045185 A ECSP045185 A EC SP045185A EC SP045185 A ECSP045185 A EC SP045185A
Authority
EC
Ecuador
Prior art keywords
active ingredient
quick release
oral formulation
fludara
pure
Prior art date
Application number
EC2004005185A
Other languages
English (en)
Inventor
Ralph Lipp
Wolfgang Heil
Ulf Tilstam
Johannes-Wilhelm Tack
Original Assignee
Schering Akti Engesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7711168&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP045185(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Akti Engesellschaft filed Critical Schering Akti Engesellschaft
Publication of ECSP045185A publication Critical patent/ECSP045185A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente invención se refiere a una formulación para comprimidos de liberación rápida con > 99,19 % de Fludara puro (Fludara purísimo) como ingrediente activo en una composición definida de las impurezas residuales.
EC2004005185A 2001-12-20 2004-07-12 Formulación oral de fludara purísimo con liberación rápida del ingrediente activo ECSP045185A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10164510A DE10164510A1 (de) 2001-12-20 2001-12-20 Orale Fludara reinst Formulierung mit schneller Freisetzung des Wirkstoffes

Publications (1)

Publication Number Publication Date
ECSP045185A true ECSP045185A (es) 2004-08-27

Family

ID=7711168

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005185A ECSP045185A (es) 2001-12-20 2004-07-12 Formulación oral de fludara purísimo con liberación rápida del ingrediente activo

Country Status (29)

Country Link
US (1) US7148207B2 (es)
EP (1) EP1455760B1 (es)
JP (2) JP2005519043A (es)
KR (1) KR100884685B1 (es)
CN (1) CN1306929C (es)
AR (1) AR037965A1 (es)
AT (1) ATE303797T1 (es)
AU (1) AU2002349043B2 (es)
BR (1) BR0215265A (es)
CA (1) CA2471396A1 (es)
DE (2) DE10164510A1 (es)
DK (1) DK1455760T3 (es)
EC (1) ECSP045185A (es)
ES (1) ES2248624T3 (es)
HR (1) HRP20040648B1 (es)
IL (2) IL162555A0 (es)
JO (1) JO2363B1 (es)
MX (1) MXPA04006005A (es)
NO (1) NO20043063L (es)
NZ (1) NZ533701A (es)
PE (1) PE20030639A1 (es)
RS (1) RS50398B (es)
RU (1) RU2318496C2 (es)
SA (1) SA03240091B1 (es)
TW (1) TWI255187B (es)
UA (1) UA78741C2 (es)
UY (1) UY27596A1 (es)
WO (1) WO2003053418A1 (es)
ZA (1) ZA200405735B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2432457A1 (en) * 2009-05-19 2012-03-28 Grindeks, A Joint Stock Company Stable pharmaceutical composition of fludarabine phosphate
US20120010216A1 (en) * 2010-07-06 2012-01-12 Brown Arthur M Pharmaceutical compositions containing vanoxerine
EP2428201A1 (en) 2010-09-08 2012-03-14 Merck Serono S.A. Oral administration of nucleoside monophosphates
CN101947208B (zh) * 2010-10-09 2012-05-23 江苏奥赛康药业股份有限公司 一种供注射用的磷酸氟达拉滨组合物及其制备方法
CN102091046B (zh) * 2011-02-12 2012-07-18 海南锦瑞制药股份有限公司 一种磷酸氟达拉滨冻干粉针剂及其制备方法
US10669302B2 (en) * 2015-08-28 2020-06-02 Zhejianf Hisun Pharmaceutical Co., Ltd. Crystal form of fludarabine phosphate, preparation method therefor, and application thereof
CN111423458A (zh) * 2020-04-29 2020-07-17 东南大学 磷酸氟达拉滨杂质h对照品的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3903297A (en) * 1973-11-01 1975-09-02 Upjohn Co Method of treatment and prophylaxis of gastric hypersecretion and gastric and duodenal ulcers using prostaglandin analogs
US4188378A (en) * 1978-01-04 1980-02-12 The United States Of America As Represented By The Department Of Health, Education And Welfare Anticancer and antiviral activity of 9-β-D-arabinofuranosyl-2-fluoroadenine
US4210745A (en) * 1978-01-04 1980-07-01 The United States Of America As Represented By The Department Of Health, Education And Welfare Procedure for the preparation of 9-β-D-arabinofuranosyl-2-fluoroadenine
US4357324A (en) * 1981-02-24 1982-11-02 The United States Of America As Represented By The Department Of Health And Human Services Prodrug derivatives of 9β-D-arabinofuranosyl-2-fluoroadenine
DE3323621A1 (de) * 1982-07-08 1984-03-01 Yamasa Shoyu K.K., Choshi, Chiba Pharmazeutisches praeparat mit die antitumor-wirkung verstaerkender wirkung, ein solches praeparat enthaltende chemotherapeutische zusammensetzung und verwendung des praeparates zur unterstuetzung der antitumor-behandlung beim menschen und tier
US5110919A (en) * 1989-12-04 1992-05-05 Ash Stevens, Inc. Process for the preparation of 2-amino-9-(2,3,5-tri-o-benzyl-beta-d-arabinofuranosyl) adenine and novel intermediates
FR2701027B1 (fr) * 1993-02-01 1997-07-18 Warner Lambert Co Procede de synthese ameliore du 9-(beta-d-arabinofuranosyl)adenine 5'-phosphate.
DE19543052A1 (de) 1995-11-06 1997-05-07 Schering Ag Verfahren zur Herstellung und Reinigung von Fludarabin-Phosphat und die Verwendung von sauren Ionenaustauschern im Verfahren
DE69713948D1 (de) * 1996-04-23 2002-08-22 Janssen Pharmaceutica Nv Rasch-freisetzende pH-unabhängige feste Dosisformen enthaltend Cisaprid
CA2210600A1 (en) * 1996-07-17 1998-01-17 Takashi Houkan Inhibitor of tumor metastasis or recurrence
US6197785B1 (en) * 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
JP4261051B2 (ja) * 1997-12-11 2009-04-30 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト リン酸フルダラビンのリチウム、ナトリウム、カリウム、カルシウム及びマグネシウム塩の製造方法、リン酸フルダラビンを製造するための精製方法及び少なくとも９９．５％の純度を有するリン酸フルダラビン
DE69934582T2 (de) 1998-06-11 2007-10-04 Pharmacia & Upjohn Co. Llc, Kalamazoo Delavirdin tablettenformulierung
US6174873B1 (en) * 1998-11-04 2001-01-16 Supergen, Inc. Oral administration of adenosine analogs
AU6646700A (en) 1999-08-20 2001-03-19 Scripps Research Institute, The Formation of heterocycles
DE60019741T2 (de) 1999-12-08 2006-03-02 Pharmacia Corp., Chicago Nanopartikelzusammensetzungen enthaltend eplerenon
US20020131988A1 (en) 1999-12-16 2002-09-19 Foster Todd P. Pharmaceutical implant containing immediate-release and sustained-release components and method of administration
US20010041697A1 (en) * 1999-12-16 2001-11-15 Foster Todd P. Implant composition containing melengestrol acetate and trenbolone acetate
US6399591B1 (en) * 2000-01-19 2002-06-04 Yung-Shin Pharmaceutical Ind. Co., Ltd. Chargeable pharmaceutical tablets

Also Published As

Publication number Publication date
ATE303797T1 (de) 2005-09-15
IL162555A0 (en) 2005-11-20
AU2002349043B2 (en) 2007-08-16
US20030176391A1 (en) 2003-09-18
UY27596A1 (es) 2003-07-31
DE50204203D1 (de) 2005-10-13
IL162555A (en) 2008-03-20
NZ533701A (en) 2006-03-31
KR20040073501A (ko) 2004-08-19
MXPA04006005A (es) 2004-09-27
ZA200405735B (en) 2006-01-25
BR0215265A (pt) 2004-12-07
NO20043063L (no) 2004-07-19
RS50398B (sr) 2009-12-31
EP1455760A1 (de) 2004-09-15
JO2363B1 (en) 2006-12-12
TW200305428A (en) 2003-11-01
JP2005519043A (ja) 2005-06-30
AU2002349043A1 (en) 2003-07-09
AR037965A1 (es) 2004-12-22
HRP20040648A2 (en) 2004-10-31
CA2471396A1 (en) 2003-07-03
ES2248624T3 (es) 2006-03-16
PL370792A1 (en) 2005-05-30
WO2003053418A1 (de) 2003-07-03
RS53304A (sr) 2006-10-27
RU2318496C2 (ru) 2008-03-10
HRP20040648B1 (en) 2012-11-30
KR100884685B1 (ko) 2009-02-18
TWI255187B (en) 2006-05-21
SA03240091B1 (ar) 2006-11-25
EP1455760B1 (de) 2005-09-07
UA78741C2 (en) 2007-04-25
DK1455760T3 (da) 2006-01-02
CN1306929C (zh) 2007-03-28
US7148207B2 (en) 2006-12-12
PE20030639A1 (es) 2003-08-28
RU2004122479A (ru) 2005-05-20
HK1077741A1 (en) 2006-02-24
JP2006137771A (ja) 2006-06-01
DE10164510A1 (de) 2003-07-10
CN1617713A (zh) 2005-05-18

Similar Documents

Publication Publication Date Title
AR106561A2 (es) Composición farmacéutica que contiene un ácido tetrahidrofólico
HN2001000190A (es) Formulaciones de liberacion sostenida para secretagogos de hormona del crecimiento
GT199900203A (es) Composiciones de celecoxib.
ES2191977T3 (es) Soluciones y dispersiones en estado solido de farmacos poco solubles en agua.
PA8559501A1 (es) Formulaciones farmaceuticas de 5,7,14-triazatetraciclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaeno
CU20060153A7 (es) Nueva forma cristalina v de agomelatina, procedimiento para su preparación y composiciones farmacéuticas que las contienen
TW200501965A (en) Highly pure fondaparinux sodium composition,process for preparing said composition and pharmaceutical compositions containing it as active principle
EA200901393A1 (ru) Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5 метил-(6s)-тетрагидрофолат
UY27886A1 (es) Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco.
ECSP045185A (es) Formulación oral de fludara purísimo con liberación rápida del ingrediente activo
BR0311327A (pt) Composição farmacêutica contendo oxcarbazepina com liberação sustentada de um ingrediente ativo
NI200700031A (es) Formulaciones de ácido hidroxamico suberoilanilida y procedimientos para la producción de las mismas
MXPA04004236A (es) Metodo para la formacion de cristales ibuprofeno.
CR9839A (es) Composicion farmaceutica fotoestable que contiene brivudina para el tratamiento de la queratitis herpetica
DK1638582T3 (da) Anvendelse af hyaluronsyre til fremstilling af kompositioner til behandling af tilbagevendende after
WO2006136580A3 (en) 2-(phenylamino)benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels
CL2004001843A1 (es) Combinacion de (a) al menos un derivado 2,5-dihidrobencenosulfonico, como el dobeilato calcico, etamsilato y persilato, y (b) al menos un modulador de los canales de potasio, composicion farmaceutica que la contiene y uso como medicamento en profilax
CO5170438A1 (es) Proceso para la preparacion de un comprimido de betahistina de liberacion controlada por granulacion en estado fundido y comprimido de liberacion controlada de betahistina obtenido mediante dicho proceso
CR7380A (es) Formulacion oral de fludara purisimo con liberacion rapida del ingrediente activo
DK1729732T3 (da) Anioniske hydrogelmatricer med pH-afhængig frigivelse som lægemiddelbærere
CU23299A3 (es) Formulaciã"n oral de fludara purã simo con liberaciã"n rã pida del ingrediente activo
UA95274C2 (ru) Твердый фармацевтический препарат, содержащий ирбесартан, и способы его изготовления
RU2008115908A (ru) Фармацевтическая композиция, содержащая гиалуронидазу и липосомы для наружного применения
EA200701686A1 (ru) Свободное основание лерканидипина
ES2190373B1 (es) Uso del acido 2-hidroxi- o 2-acetiloxi-4-trifluorometilbenzoico como agente para el tratamiento y prevencion del deterioro cognitivo ligero.